Odactra DERMATOPHAGOIDES PTERONYSSINUS and DERMATOPHAGOIDES FARINAE 6 [arb'U]/1; 6 [arb'U]/1 Tablet, 5-count — NDC 52709-1701-5 (Billing 52709-1701-05)
This is a package of 5 tablets of Odactra DERMATOPHAGOIDES PTERONYSSINUS and DERMATOPHAGOIDES FARINAE 6 [arb'U]/1; 6 [arb'U]/1 Tablet from ALK-Abello A S, first listed with the FDA Jan 2018 and currently FDA-listed.
NDC database record
One package, one record: these facts belong to NDC 52709-1701-5 alone.
- Record
- FDA NDC Directory package listing · Standardized allergenic
- Code segments
- 52709 labeler · 1701 product · 5 package
- Package marketed since
- Jan 1, 2018
- Sample package
- No — commercial package
- Listing certified through
- Dec 31, 2027
- Barcode (UPC-A, from the NDC)
- 3 5270917015 8
- FDA record last changed
- Nov 19, 2026
Identity & classification
Regulatory identifiers FDA, NLM and CMS codes for this package
Drug-database identifiers Medi-Span GPI and First Databank GCN / HICL / AHFS classification
- GSN (GCN sequence number): 076750
- GCN: 42527
- GPI-14 (Medi-Span): 20109902220740
- HICL (First Databank): 034376
- AHFS class code: 80:02.00.00
Where does this data come from?
- FDA openFDA NDC Directory · synced Nov 19, 2026
- FDA label on DailyMed · label index refreshed Nov 20, 2026
- RxNorm (NLM RxNav) · catalog refreshed Nov 19, 2026
- Medi-Span GPI (licensed)
- First Databank (licensed) · refreshed Nov 19, 2026
Clinical
Patient education
Supplement & herbal interactions
Where does this data come from?
- MedlinePlus (NLM) · refreshed Nov 19, 2026
- FDA label on DailyMed · label index refreshed Nov 20, 2026
Ask a licensed pharmacist directly — free, answered by our team.
Pricing
A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.
| Price system | Per each | Per package |
|---|---|---|
| Retail pharmacies payNADAC · weekly | Not in the retail survey — common for institutional, discontinued, or low-volume packs. | |
| Medicaid paysCMS SDUD · 12 mo | No recent Medicaid claims on file for this NDC — rare and low-volume NDCs are suppressed in the public data. | |
| Medicare drug plans payPart D · quarterly | No Part D plan price is available for this NDC in our data. | |
Where does this data come from?
- CMS NADAC weekly file
- CMS ASP pricing files · refreshed Nov 20, 2026
- CMS Medicaid State Drug Utilization Data · refreshed Nov 19, 2026
- CMS Part D plan pricing files · refreshed Oct 24, 2026
- VA National Acquisition Center price file
Packaging — all sizes for this product
| Package NDC | Description | Per unit | Per pack | Marketing start | Marketing end | Status |
|---|---|---|---|---|---|---|
| 52709-1701-03 52709-1701-3 Main listing | 3 BLISTER PACK in 1 CARTON / 10 TABLET in 1 BLISTER PACK Inner NDC 52709-1701-1 · each blister pack (10 tablets) | $11.71 / ea | $351.32 | 2018-01-01 | — | Active |
| 52709-1701-05 You're viewing this | 1 BLISTER PACK in 1 CARTON / 5 TABLET in 1 BLISTER PACK | — | — | 2018-01-01 | — | Active |
This pack shows little to no recent Medicaid volume — a different pack size carries most fills. See all packs ↓
Pack size FAQ
What quantity is in this package?
How does this package differ from NDC 52709-1701-03?
What NDC number is used to bill for this package of Odactra DERMATOPHAGOIDES PTERONYSSINUS and DERMATOPHAGOIDES FARINAE 6 [arb'U]/1; 6 [arb'U]/1 Tablet?
Prices are the latest CMS NADAC pharmacy acquisition cost per NDC; per-pack figures are per-unit × pack quantity, shown only when the pack is denominated in the same measure NADAC prices.
Therapeutic equivalents
| Product | Labeler | Pack | NADAC/unit | TE | Status | Price vs. this |
|---|---|---|---|---|---|---|
| Odactra 6 [arb'U]/1; 6 [arb'U]this 52709-1701-05 | ALK-Abello | 5 tablets | — | — | FDA listed | — |
Where does this data come from?
- FDA openFDA NDC Directory · synced Nov 19, 2026
- FDA Purple Book · refreshed Nov 5, 2026
- CMS NADAC weekly file
Availability & biosimilar status
Biologics have no small-molecule generics; biosimilar competition is tracked in the FDA Purple Book.
Why the date isn’t exact: Biosimilar timing can change because patents may be challenged, settled, licensed, added or removed, and litigation can move the real date earlier or later.
🛈 What do these terms mean?
- Biologic patent
- A patent the reference product’s maker has publicly listed. A biosimilar generally can’t launch until these expire — unless they’re invalidated or resolved in a settlement.
- Reference-product exclusivity
- A flat 12 years of FDA market protection from the biologic’s first licensure (the BPCIA). No biosimilar can be licensed before it ends, regardless of patents.
- Interchangeable exclusivity
- The first interchangeable biosimilar can earn a period as the only interchangeable version (pharmacists can substitute it without the prescriber).
- Earliest biosimilar (LOE)
- The latest of all the dates above — the soonest a biosimilar can realistically reach the market. Litigation and settlements can move it earlier.
Biologics have no small-molecule “generics” — competition comes from FDA-licensed biosimilars, tracked in the FDA Purple Book.
| Code | What it grants | Expires |
|---|---|---|
| RefProduct | Reference-product exclusivity (12-year, BPCIA) — no biosimilar can be licensed before this date | Mar 1, 2029 |
Is there a biosimilar for ODACTRA 12 SQ-HDM SL TABLET?
Why do different websites show different biosimilar dates?
Can a biosimilar launch before the last patent expires?
What does “current Purple Book estimate” mean?
What does “FDA listed” mean?
What does a patent or protection date mean here?
Where does this data come from?
- FDA Purple Book · refreshed Nov 5, 2026
What it looks like
Where does this data come from?
- FDA label on DailyMed · label index refreshed Nov 20, 2026
Inactive Ingredients / Excipients
Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.
💡 Tap an ingredient (hover on desktop) to see what it is and why it’s used.
-
UNII 3OWL53L36A
A natural sugar alcohol derived from seaweed or synthesized in the lab. It's used as a filler to add bulk, a sweetener in sugar-free formulas, and a disintegrant to help tablets break apart in the stomach.
-
UNII JSM64OJO9B
A protein derived from fish or shellfish, used as a capsule material or binder in medicines. It helps hold ingredients together and forms the outer shell of soft gel capsules.
-
UNII AHQ60JKI5D
A protein derived from fish or marine animals, used as a capsule material or binder in medications. Its high molecular weight helps form sturdy capsule shells that contain and protect the active drug inside.
-
UNII 55X04QC32I
A strong alkaline chemical used to adjust and maintain the pH balance of liquid medicines. It helps keep the medicine stable and ensures it stays effective during storage.
4 inactive ingredients listed in the exact product block matched to this NDC.
Where does this data come from?
ingredient classCode="IACT" elements from the exact product block matched by this NDC. Label-section narrative from DailyMed / the openFDA label index is shown separately when available.- FDA label on DailyMed · label index refreshed Nov 20, 2026
- FDA openFDA NDC Directory · synced Nov 19, 2026
Inactive ingredient FAQ
Are inactive ingredients the same for every manufacturer?
Why might an inactive ingredient be missing?
Can inactive ingredients matter?
Manufacturer & labeler
More NDCs from ALK-Abello A S labeler code 52709
Where does this data come from?
- FDA openFDA NDC Directory · synced Nov 19, 2026
- Drugs@FDA
Full FDA label FDA SPL
🚨 Boxed Warning ▾
WARNING: SEVERE ALLERGIC REACTIONS ODACTRA can cause life-threatening allergic reactions such as anaphylaxis and severe laryngopharyngeal restriction. ( 5.1 ) Do not administer ODACTRA to patients with severe, unstable or uncontrolled asthma. ( 4 ) Observe patients in the office for at least 30 minutes following the initial dose.
( 5.1 ) Prescribe epinephrine, instruct and train patients or parents/guardians on its appropriate use, and instruct patients or parents/guardians to seek immediate medical care upon its use. ( 5.1 ) ODACTRA may not be suitable for patients with certain underlying medical conditions that may reduce their ability to survive a serious allergic reaction. ( 5.1 ) ODACTRA may not be suitable for patients who may be unresponsive to epinephrine or inhaled bronchodilators, such as those taking beta-blockers.
( 5.1 ) WARNING: SEVERE ALLERGIC REACTIONS See full prescribing information for complete boxed warning. • ODACTRA can cause life-threatening allergic reactions such as anaphylaxis and severe laryngopharyngeal restriction . ( 5.1 ) • Do not administer ODACTRA to patients with severe, unstable or uncontrolled asthma . ( 4 ) • Observe patients in the office for at least 30 minutes following the initial dose.
( 5.1 ) • Prescribe epinephrine, instruct and train patients or parents/guardians on its appropriate use, and instruct patients or parents/guardians to seek immediate medical care upon its use. ( 5.1 ) • ODACTRA may not be suitable for patients with certain underlying medical conditions that may reduce their ability to survive a serious allergic reaction. ( 5.1 ) • ODACTRA may not be suitable for patients who may be unresponsive to epinephrine or inhaled bronchodilators, such as those taking beta-blockers.
( 5.1 )
🎯 Indications and Usage ▾
1 INDICATIONS AND USAGE ODACTRA ™ is an allergen extract indicated as immunotherapy for the treatment of house dust mite (HDM)-induced allergic rhinitis, with or without conjunctivitis, confirmed by positive in vitro testing for IgE antibodies to Derma t ophagoides farinae or Dermatophagoides pteronyssinus house dust mites, or by positive skin testing to licensed house dust mite allergen extracts. ODACTRA is approved for use in individuals 5 through 65 years of age. ODACTRA is not indicated for the immediate relief of allergic symptoms.
ODACTRA is an allergen extract indicated as immunotherapy for the treatment of house dust mite (HDM)-induced allergic rhinitis, with or without conjunctivitis, confirmed by positive in vitro testing for IgE antibodies to Dermatophagoides farina e or Dermatophagoides pteronyssinus house dust mites or by positive skin testing to licensed house dust mite allergen extracts. ODACTRA is approved for use in individuals 5 through 65 years of age. ( 1 )
⏱️ Dosage and Administration ▾
2 DOSAGE AND ADMINISTRATION Administer sublingually. Administer sublingually ( 2 ) One tablet daily. ( 2.1 ) Place the tablet immediately under the tongue where it will dissolve within 10 seconds.
Allow it to remain there until completely dissolved. Do not swallow for at least 1 minute. ( 2.2 ) Administer the first dose of ODACTRA under the supervision of a healthcare professional with experience in the diagnosis and treatment of allergic diseases.
Observe patients in the office for at least 30 minutes following the initial dose. ( 2.2 )
2.1Dos e One ODACTRA tablet daily. 2. 2 Administration Administer the first dose of ODACTRA in a healthcare setting under the supervision of a healthcare professional with experience in the diagnosis and treatment of allergic diseases.
After receiving the first dose of ODACTRA, observe the patient for at least 30 minutes to monitor for signs or symptoms of a severe systemic or a severe local allergic reaction. If the patient tolerates the first dose, the patient may take subsequent doses at home. The patient should administer ODACTRA as follows: Take the tablet from the blister unit after carefully removing the foil with dry hands.
Place the tablet immediately under the tongue where it will dissolve within 10 seconds. Do not swallow for at least 1 minute. Wash hands after handling the tablet.
Do not take the tablet with food or beverage. Food or beverage should not be taken for 5 minutes after taking the tablet. Data regarding the safety of restarting treatment after missing a dose of ODACTRA are limited.
In the clinical studies, treatment interruptions for up to seven days were allowed. Prescribe epinephrine to patients prescribed ODACTRA and instruct patients (or their parents/guardians) in the proper use of epinephrine [see Warnings and Precautions ( 5.1 ) ] .
💊 Dosage Forms and Strengths ▾
3 DOSAGE FORMS AND STRENGTHS ODACTRA is available as 12 SQ-HDM* sublingual tablets that are white to off-white, circular with a debossed pentagon detail on one side. *SQ-HDM is the dose unit for ODACTRA. SQ is a method of standardization of biological potency, major allergen content and complexity of the allergen extract. HDM is an abbreviation for house dust mite. Sublingual tablet, 12 SQ-HDM. ( 3 )
⛔ Contraindications ▾
4 CONTRAINDICATIONS ODACTRA is contraindicated in patients with: Severe, unstable or uncontrolled asthma A history of any severe systemic allergic reaction A history of any severe local reaction after taking any sublingual allergen immunotherapy A history of eosinophilic esophagitis Hypersensitivity to any of the inactive ingredients contained in this product [see Description ( 11 )] Severe, unstable or uncontrolled asthma. ( 4 ) History of any severe systemic allergic reaction or any severe local reaction to sublingual allergen immunotherapy.
( 4 ) A history of eosinophilic esophagitis. ( 4 ) Hypersensitivity to any of the inactive ingredients contained in this product. ( 4 )
⚠️ Warnings and Cautions ▾
5 WARNINGS AND PRECAUTIONS Inform patients or parents/guardians of the signs and symptoms of serious allergic reactions and instruct them to seek immediate medical care and discontinue therapy should any of these occur. ( 5.1 ) In case of oral inflammation or wounds, stop treatment with ODACTRA to allow complete healing of the oral cavity. ( 5.6 )
5.1Severe Allergic Reactions ODACTRA can cause systemic allergic reactions including anaphylaxis which may be life-threatening. In addition, ODACTRA can cause severe local reactions, including laryngopharyngeal swelling, which can compromise breathing and be life-threatening. Allergic reactions may require treatment with epinephrine.
Prescribe epinephrine to patients receiving ODACTRA. Instruct patients or their parents/guardians to recognize the signs and symptoms of a severe allergic reaction and in the proper use of emergency epinephrine. Instruct patients or their parents/guardians to seek immediate medical care and to stop treatment with ODACTRA upon use of epinephrine [see Patient Counseling Information ( 17 ) ].
See Prescribing Information for epinephrine for complete information. ODACTRA may not be suitable for patients with certain medical conditions that may reduce the ability to survive a serious allergic reaction or that may increase the risk of adverse reactions after epinephrine administration. Examples of these medical conditions include but are not limited to: markedly compromised lung function (either chronic or acute); severe mast cell disorder; or cardiovascular disease including unstable angina, recent myocardial infarction, significant arrhythmia, and uncontrolled hypertension.
In addition, ODACTRA may not be suitable for patients who are taking medications that can potentiate or inhibit the effects of epinephrine (see Prescribing Information for epinephrine for information on drug interactions). Administer the initial dose of ODACTRA in a healthcare setting under the supervision of a healthcare professional with experience in the diagnosis and treatment of allergic diseases and prepared to manage a life-threatening systemic or local allergic reaction. Observe patients in the office for at least 30 minutes following the initial dose of ODACTRA.
5. 2 Upper Airway Compromise ODACTRA can cause local reactions in the mouth or throat that could compromise the upper airway [see Adverse Reactions ( 6.1 )] . Consider discontinuation of ODACTRA in patients who experience persistent and escalating adverse reactions in the mouth or throat.
5. 3 Eosinophilic Esophagitis Eosinophilic esophagitis has been reported in association with sublingual tablet immunotherapy [see Contraindications ( 4 )] . Discontinue ODACTRA and consider a diagnosis of eosinophilic esophagitis in patients who experience severe or persistent gastroesophageal symptoms including dysphagia or chest pain.
5. 4 Asthma Withhold immunotherapy with ODACTRA if the patient is experiencing an acute asthma exacerbation. Re-evaluate patients who have recurrent asthma exacerbations and consider discontinuation of ODACTRA.
5. 5 Concomitant Allergen Immunotherapy ODACTRA has not been studied in participants who are receiving concomitant allergen immunotherapy. Concomitant dosing with other allergen immunotherapy may increase the likelihood of local or systemic adverse reactions to either subcutaneous or sublingual allergen immunotherapy.
5. 6 Oral Conditions Stop treatment with ODACTRA to allow complete healing of the oral cavity in patients with oral inflammation (e.g., oral lichen planus, mouth ulcers, or thrush) or oral wounds, such as those following oral surgery, tooth loss or dental extraction.
🤒 Adverse Reactions ▾
6 ADVERSE REACTIONS The most common solicited adverse reactions reported in ≥10% of adult participants (18 through 65 years of age) treated with ODACTRA were: throat irritation/tickle, itching in the mouth, itching in the ear, swelling of the uvula/back of the mouth, swelling of the lips, swelling of the tongue, tongue pain, nausea, throat swelling, stomach pain, tongue ulcer/sore on the tongue, mouth ulcer/sore in the mouth, and food tastes different. The most common solicited adverse reactions reported in ≥10% of adolescent participants (12 through 17 years of age) treated with ODACTRA were: throat irritation/tickle, itching in the mouth, itching in the ear, tongue pain, stomach pain, swelling of the uvula/back of the mouth, swelling of the lips, swelling of the tongue, throat swelling, nausea, tongue ulcer/sore on the tongue, and mouth ulcer/sore in the mouth, and diarrhea.
The most common solicited adverse reactions reported in ≥10% of pediatric participants (5 through 11 years of age) treated with ODACTRA were itching in the mouth, throat irritation/tickle, itching in the ear, stomach pain, swelling of the lips, tongue pain, food tastes different, nausea (feel like throwing up), swelling in the back of the mouth, swelling of the tongue, and mouth ulcer. The most common solicited adverse reactions reported in ≥10% of adult participants (18 through 65 years of age) treated with ODACTRA were: throat irritation/tickle, itching in the mouth, itching in the ear, swelling of the uvula/back of the mouth, swelling of the lips, swelling of the tongue, tongue pain, nausea, throat swelling, stomach pain, tongue ulcer/sore on the tongue, mouth ulcer/sore in the mouth, and food tastes different.
( 6.1 ) The most common solicited adverse reactions reported in ≥10% of adolescent participants (12 through 17 years of age) treated with ODACTRA were: throat irritation/tickle, itching in the mouth, itching in the ear, tongue pain, stomach pain, swelling of the uvula/back of the mouth, swelling of the lips, swelling of the tongue, throat swelling, nausea, tongue ulcer/sore on the tongue, and mouth ulcer/sore in the mouth, and diarrhea. ( 6.1 ) The most common solicited adverse reactions reported in ≥10% of pediatric participants (5 through 11 years of age) treated with ODACTRA were: itching in the mouth, throat irritation/tickle, itching in the ear, stomach pain, swelling of the lips, tongue pain, food tastes different, nausea (feel like throwing up), swelling in the back of the mouth, swelling of the tongue, and mouth ulcer.
( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact ALK-Abelló Inc., a subsidiary of ALK-Abelló A/S, at 1-855-216-6497 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
6.1Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice. Adults (18 through 65 years of age) In four double-blind, placebo-controlled, randomized clinical studies, a total of 1279 participants with house dust mite-induced allergic rhinitis, with or without conjunctivitis, 18 through 65 years of age was treated with at least one dose of ODACTRA 12 SQ-HDM.
Of participants treated with ODACTRA in the four studies, 50% had mild to moderate asthma and 71% were polysensitized to other allergens in addition to HDM, including trees, grasses, weeds, molds, and animal danders. The study population was 88% White, 6% African American, 4% Asian and 55% female. Study 1 (NCT01700192) was a randomized, double-blind, placebo-controlled study conducted in the US and Canada evaluating ODACTRA in 1482 participants 12 years of age and older with house dust mite-induced allergic rhinitis with or without conjunctivitis.
Of the 1482 participants, 640 participants 18 through 65 years of age received at least one dose of ODACTRA, with a… [Excerpted — this section continues on DailyMed.]
👥 Use in Specific Populations ▾
8 USE IN SPECIFIC POPULATIONS
8.1Pregnancy Risk Summary All pregnancies have a risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. Available data on ODACTRA administered to pregnant women are insufficient to inform associated risks in pregnancy.
In an embryo/fetal developmental toxicity study performed in mice, administration of ODACTRA during gestation did not reveal adverse developmental outcomes in fetuses [ see Data ( 8.1 ) ]. Data Animal Data In a developmental toxicity study, the effect of ODACTRA on embryo/fetal development was evaluated in mice. Animals were administered ODACTRA subcutaneously daily from day 6 to day 17 of the gestation period at doses up to 5 times the human sublingual dose.
There were no ODACTRA-related post-implantation losses, fetal malformations or variations. 8. 2 Lactation Risk Summary It is not known whether ODACTRA is excreted in human milk.
Data are not available to assess the effects of ODACTRA on the breastfed child or on milk production and excretion in the nursing woman. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for ODACTRA and any potential adverse effects on the breastfed child from ODACTRA or from the underlying maternal condition.
8.4Pediatric Use The safety and effectiveness of ODACTRA have been established in individuals 5 through 17 years of age with HDM-induced allergic rhinitis, with or without conjunctivitis. [ s ee Adverse Reactions ( 6.1 ) and C linical S tudies ( 14 ) ] . The safety and effectiveness have not been established in individuals below 5 years of age.
8.5Geriatric Use Safety and effectiveness have not been established in individuals older than 65 years of age.
🤰 Pregnancy ▾
8.1Pregnancy Risk Summary All pregnancies have a risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. Available data on ODACTRA administered to pregnant women are insufficient to inform associated risks in pregnancy.
In an embryo/fetal developmental toxicity study performed in mice, administration of ODACTRA during gestation did not reveal adverse developmental outcomes in fetuses [ see Data ( 8.1 ) ]. Data Animal Data In a developmental toxicity study, the effect of ODACTRA on embryo/fetal development was evaluated in mice. Animals were administered ODACTRA subcutaneously daily from day 6 to day 17 of the gestation period at doses up to 5 times the human sublingual dose.
There were no ODACTRA-related post-implantation losses, fetal malformations or variations.
🧒 Pediatric Use ▾
8.4Pediatric Use The safety and effectiveness of ODACTRA have been established in individuals 5 through 17 years of age with HDM-induced allergic rhinitis, with or without conjunctivitis. [ s ee Adverse Reactions ( 6.1 ) and C linical S tudies ( 14 ) ] . The safety and effectiveness have not been established in individuals below 5 years of age.
🧓 Geriatric Use ▾
8.5Geriatric Use Safety and effectiveness have not been established in individuals older than 65 years of age.
🆘 Overdosage ▾
10 OVERDOSAGE Symptoms of overdose may include hypersensitivity reactions such as systemic allergic reactions or severe local allergic reactions [see Warnings and Precautions ( 5.1 )] . In case of severe adverse reactions such as angioedema, difficulty in swallowing, difficulty in breathing, changes in voice, or feeling of fullness in the throat, immediate medical evaluation is needed. These reactions should be treated as medically indicated, including the use of epinephrine as appropriate [see Warnings and Precautions ( 5.1 )] .
🧬 Clinical Pharmacology ▾
12 CLINICAL PHARMACOLOGY
12.1Mechanism of Action The precise mechanisms of action of allergen immunotherapy have not been fully established.
🧬 Mechanism of Action ▾
12.1Mechanism of Action The precise mechanisms of action of allergen immunotherapy have not been fully established.
📦 How Supplied / Storage and Handling ▾
16 HOW SUPPLIED/STORAGE AND HANDLING ODACTRA 12 SQ-HDM tablets are white to off-white, circular freeze-dried sublingual tablets with a debossed pentagon detail on one side. ODACTRA is supplied as follows: 3 blister packages of 10 tablets (30 tablets total). NDC 52709-1701-3 Store at controlled room temperature, 20ºC-25ºC (68ºF-77ºF). Store in the original package until use to protect from moisture.
📋 Description ▾
11 DESCRIPTION ODACTRA tablets contain house dust mite allergen extract from Dermatophagoides farinae and Dermatophagoides pteronyssinus . ODACTRA is a sublingual tablet that dissolves within 10 seconds. ODACTRA is available as a tablet of 12 SQ-HDM [6 SQ-HDM D. farina e and 6 SQ-HDM D. pteronyssinus ].
Each tablet contains a 1:1:1:1 potency ratio of D. farinae group 1 allergen, D. farinae group 2 allergen, D. pteronyssinus group 1 allergen, and D. pteronyssinus group 2 allergen. Inactive ingredients: gelatin NF (fish source), mannitol USP, and sodium hydroxide NF.
💬 Information for Patients ▾
17 PATIENT COUNSELING INFORMATION Advise patients (or their parents/guardians) to read the FDA-approved patient labeling ( Medication Guide ) and to keep ODACTRA and all medicines out of the reach of children. Severe Allergic Reactions Advise patients (or their parents/guardians) that ODACTRA may cause life-threatening systemic or local allergic reactions, including anaphylaxis. Educate patients (or their parents/guardians) about the signs and symptoms of these allergic reactions [see Warnings and Precautions ( 5.1 )] .
The signs and symptoms of a severe allergic reaction may include: syncope, dizziness, hypotension, tachycardia, dyspnea, wheezing, bronchospasm, chest discomfort, cough, abdominal pain, vomiting, diarrhea, rash, pruritus, flushing, and urticaria. Ensure that patients (or their parents/guardians) have epinephrine and instruct patients (or their parents/guardians) in its proper use. Instruct patients (or their parents/guardians) who experience a severe allergic reaction to seek immediate medical care, discontinue ODACTRA, and resume treatment only when advised by a healthcare professional to do so [ s ee Warnings and Precautions ( 5.1 ). ] Advise patients to read the patient information for epinephrine.
Inform patients (or their parents/guardians) that the first dose of ODACTRA must be administered in a healthcare setting under the supervision of a healthcare professional and that they will be monitored for at least 30 minutes to watch for signs and symptoms of life-threatening systemic or local allergic reaction [see Warnings and Precautions ( 5.1 )] . Because of the risk of upper airway compromise, instruct patients (or their parents/guardians) with persistent and escalating adverse reactions in the mouth or throat to discontinue ODACTRA and to contact their healthcare professional [ s ee Warnings and Precautions ( 5.2 )] .
Because of the risk of eosinophilic esophagitis, instruct patients (or their parents/guardians) with severe or persistent symptoms of esophagitis to discontinue ODACTRA and to contact their healthcare professional [ s ee Warnings and Precautions ( 5.3 )] . Asthma Instruct patients (or their parents/guardians) with asthma that if they have difficulty breathing or if their asthma becomes difficult to control, they should stop taking ODACTRA and contact their healthcare professional immediately [see Warnings and Precautions ( 5.4 ) ] .
Administration Instructions Instruct patients (or their parents/guardians) to carefully remove the foil from the blister unit with dry hands and then take the sublingual tablet immediately by placing it under the tongue where it will dissolve within 10 seconds. Instruct patients to avoid swallowing for at least 1 minute. Also instruct patients to wash their hands after handling the tablet, and to avoid food or beverages for 5 minutes after taking the tablet [ s ee Dosage and Administration ( 2.2 ) ] .
Advise patients (or their parents/guardians) who miss more than one dose of ODACTRA to contact their healthcare professional before restarting [see Warning and Precautions ( 5.1 )] . Manufactured for: ALK-Abelló A/S ALK-Abelló A/S, Bøge Allé 6-8, DK-2970 Hørsholm, Denmark U.S. License No.
1292 Manufactured by: Catalent Pharma Solutions Limited, Blagrove, Swindon, Wiltshire, SN5 8RU UK © 2026 ALK-Abelló A/S All rights reserved. ALK
💬 Medication Guide ▾
MEDICATION GUIDE ODACTRA™ (OH-dack-trah) House Dust Mite ( Dermatophagoides farinae and Dermatophagoides pteronyssinus ) Allergen Extract Sublingual Tablets Carefully read this Medication Guide before you or your child starts taking ODACTRA and each time you get a refill. This Medication Guide does not take the place of talking with your healthcare provider about your or your child’s medical condition or treatment. Talk with your healthcare provider if there is something you do not understand or if you want to learn more about ODACTRA.
What is the Most Important Information I Should Know about ODACTRA? ODACTRA can cause severe allergic reactions that may be life-threatening. Stop taking ODACTRA and get medical treatment right away if you or your child has any of the following symptoms after taking ODACTRA: Trouble breathing Throat tightness or swelling Trouble swallowing or speaking Dizziness or fainting Rapid or weak heartbeat Severe stomach cramps or pain, vomiting, or diarrhea Severe flushing or itching of the skin For home administration of ODACTRA, your doctor will prescribe epinephrine, a medicine you can use if you or your child has a severe allergic reaction after taking ODACTRA.
Your doctor will train and instruct you on the proper use of epinephrine. Talk to your doctor or read the epinephrine patient information if you have any questions about the use of epinephrine. What is ODACTRA?
ODACTRA is a prescription medicine used for sublingual (under the tongue) immunotherapy to treat house dust mite allergies that can cause sneezing, runny or itchy nose, stuffy or congested nose, or itchy and watery eyes. ODACTRA may be prescribed for persons 5 through 65 years of age who are allergic to house dust mites. ODACTRA is NOT a medication that gives immediate relief for symptoms of house dust mite allergy.
Who Should Not Take ODACTRA? You or your child should not take ODACTRA if you or your child: has severe, unstable or uncontrolled asthma had a severe allergic reaction in the past that included any of these symptoms: Trouble breathing Dizziness or fainting Rapid or weak heartbeat has ever had difficulty with breathing due to swelling of the throat or upper airway after using any sublingual immunotherapy before. has ever been diagnosed with eosinophilic esophagitis. is allergic to any of the inactive ingredients contained in ODACTRA.
The inactive ingredients contained in ODACTRA are: gelatin, mannitol, and sodium hydroxide. What Should I Tell My Doctor Before Taking ODACTRA? Your doctor may decide that ODACTRA is not the best treatment if you or your child: has asthma, depending on how severe it is. suffers from lung disease such as chronic obstructive pulmonary disease (COPD). suffers from heart disease such as coronary artery disease, an irregular heart rhythm, or you or your child has hypertension that is not well controlled. is pregnant, plans to become pregnant during the time you will be taking ODACTRA, or is breast-feeding. is unable or unwilling to administer epinephrine to treat a severe allergic reaction to ODACTRA. is taking certain medicines that enhance the likelihood of a severe reaction, or interfere with the treatment of a severe reaction.
These medicines include: beta blockers and alpha-blockers (prescribed for high blood pressure) cardiac glycosides (prescribed for heart failure or problems with heart rhythm) diuretics (prescribed for heart conditions and high blood pressure) ergot alkaloids (prescribed for migraine headache) monoamine oxidase inhibitors or tricyclic antidepressants (prescribed for depression) thyroid hormone (prescribed for low thyroid activity). is receiving allergy shots or other immunotherapy under the tongue. Use of more than one of these types of medicines together may increase the likelihood of a severe allergic reaction.
You should tell your doctor if you or your child is taking or has recently taken any other medicines, including medicines obtained without a prescription and herbal… [Excerpted — this section continues on DailyMed.]
🔬 Clinical Studies ▾
14 CLINICAL STUDIES The efficacy of ODACTRA for the treatment of HDM-induced allergic rhinitis was investigated in three double-blind, placebo-controlled, randomized clinical field efficacy studies (Studies 1, 2, and 6) and one environmental exposure chamber (EEC) study (Study 3). Adolescents and A dults Study 1 (North American Field Efficacy Study) Study 1 was a double-blind, placebo-controlled, randomized field efficacy study conducted in the United States and Canada for a duration of up to 12 months, that compared the efficacy of ODACTRA (N=741) compared to placebo (N=741) in the treatment of HDM-induced allergic rhinitis.
Participants 12 through 85 years of age were enrolled if they had a history of symptomatic allergic rhinitis and were sensitized to D. farinae and/or D. pteronyssinus as determined by house dust mite specific IgE. Participants were required to be symptomatic and were not taking symptom-relieving allergy medications at enrollment. Participants with mild to moderate asthma, defined as asthma of a severity that required, at most, a daily medium dose of an inhaled corticosteroid, were enrolled in the study.
In this study, 31% of participants had asthma, 48% had conjunctivitis, and 76% were polysensitized to other allergens in addition to HDM, including trees, grasses, weed, animal danders and molds. The participant population was 76% White, 11% African American, 7% Asian, and 59% female. The mean age of participants was 35 years.
The efficacy of ODACTRA in the treatment of HDM-induced allergic rhinitis was assessed through self-reporting of symptoms and medication use. Based on these self-assessments, the Total Combined Rhinitis Score (TCRS), daily symptom scores (DSS) and daily medication scores (DMS) for rhinoconjunctivitis were calculated. Daily symptoms included four nasal symptoms (runny nose, stuffy nose, sneezing, and itchy nose) and two ocular symptoms (gritty/itchy eyes and watery eyes).
Each of these rhinoconjunctivitis symptoms was individually graded by participants daily on a scale of 0 (none) to 3 (severe) and then summed. Participants in active and placebo arms of this study were allowed to take symptom-relieving allergy medications (including oral and ocular antihistamines and nasal corticosteroids) during the study as needed. The DMS measured the use of these standard symptom-relieving allergy medications.
Predefined daily maximum scores were assigned to each class of rhinitis and conjunctivitis medication as 0=none, 6=oral antihistamine, 6=ocular antihistamine, and 8=nasal corticosteroid. The primary endpoint was the difference between the treatment and placebo groups in the average TCRS during approximately the last 8 weeks of treatment. The TCRS represents the sum of the daily rhinitis DSS and the rhinitis DMS.
Other secondary endpoints in this study included the average rhinitis DSS, the average rhinitis DMS, and the Total Combined Score (TCS). The TCS represents the sum of the rhinoconjunctivitis DSS and the rhinoconjunctivitis DMS, which was then averaged during approximately the last 8 weeks of treatment. Participants in this study were required to stop taking symptom-relieving allergy medication during the baseline period.
The mean rhinitis DSS at baseline was 7.94 out of 12 total points in both the treatment arm and in the placebo arm. The results of this study are shown in Table 6. Consistent results across age groups were observed, supporting a similar treatment effect in adolescent and adult subgroups.
Table 6: Total Combined Rhinitis Score (TCRS), Rhinitis Daily Symptom Score (DSS), Rhinitis Daily Medication Score (DMS), and Total Combined Score (TCS) During the Last 8 Weeks of Treatment with ODACTRA in Participants 12 Years of Age and Older (Study 1, Field Efficacy Study) Endpoint* ODACTRA (n=566) † Score ‡ Placebo (n=620) † Score ‡ Treatment Difference (ODACTRA- Placebo) Difference Relative to Placebo § Estimate (95% CI) Primary Endpoint TCRS ¶ 4.10 4.95 -0.80 -17.2% (-25.0%, -… [Excerpted — this section continues on DailyMed.]
🧪 Nonclinical Toxicology ▾
13 NONCLINICAL TOXICOLOGY
13.1Carcinogenesis, Mutagenesis, Impairment of Fertility ODACTRA has not been evaluated for carcinogenic potential or impairment of fertility in animals. Two in vitro chromosome aberration assays, an in vitro bacterial mutagenesis assay and a combined in vivo Comet and micronucleus assay for mutagenicity in rats were performed using HDM ( D. farinae and D. pteronyssinus ) allergen extracts. One in vitro chromosome aberration assay was positive.
Based on the aggregated results, the weight of evidence indicates that this finding is unlikely to be of clinical relevance.
📄 Carcinogenesis, Mutagenesis, Impairment of Fertility ▾
13.1Carcinogenesis, Mutagenesis, Impairment of Fertility ODACTRA has not been evaluated for carcinogenic potential or impairment of fertility in animals. Two in vitro chromosome aberration assays, an in vitro bacterial mutagenesis assay and a combined in vivo Comet and micronucleus assay for mutagenicity in rats were performed using HDM ( D. farinae and D. pteronyssinus ) allergen extracts. One in vitro chromosome aberration assay was positive.
Based on the aggregated results, the weight of evidence indicates that this finding is unlikely to be of clinical relevance.
📄 Package Label / Principal Display Panel ▾
PRINCIPAL DISPLAY PANEL NDC 52709-1701-3 House Dust Mite ( Dermatophagoides farinae and Dermatophagoides pteronyssinus ) Allergen Extract ODACTRA Sublingual Tablets 3 blister packages of 10 tablets (30 tablets total). PRINCIPAL DISPLAY PANEL NDC 52709-1701-3 House Dust Mite (Dermatophagoides farinae and Dermatophagoides pteronyssinus) Allergen Extract ODACTRA Sublingual Tablets 3 blister packages of 10 tablets (30 tablets total).
Medicaid utilization by pack size
Medicare Part D spend CMS · PART D · 2026 (Q1)
About this NDC listing & data coverage
What data is (and isn’t) available for this NDC — tap to expand
| NDC identity (package / product / labeler codes) | ✓ Available |
| Labeler | ✓ Available |
| Product & package description | ✓ Available |
| Marketing category & status | ✓ Available |
| Active ingredient / dosage form / route | ✓ Available |
| FDA label (SPL via DailyMed) | ✓ Available |
| Package photos | ✓ Available |
| Inactive ingredients (structured) | ✓ Available |
| NADAC pharmacy acquisition price (CMS) | — Not published for this NDC CMS publishes NADAC only for NDCs reported in its retail-pharmacy survey. |
| Orange Book / therapeutic-equivalence data | ✓ Available |
| HCPCS J-code billing crosswalk | — Not published for this NDC Most self-administered / retail products have no J-code — that is normal. |
| Medicaid utilization (CMS SDUD) | — Not published for this NDC CMS reports utilization only for NDCs with Medicaid claims above its privacy threshold. |